In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Cymabay Therapeutics Inc.. Trade Record

NASDAQ:CBAY Cymabay Therapeutics Inc. stock gains 93.65% Exit Mar 21, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart CBAY Feb 7, 2017, priceSeries
About Cymabay Therapeutics Inc.

Cymabay Therapeutics, Inc. focuses on developing therapies to treat metabolic diseases. Its key clinical development candidates comprise MBX-8025, a selective agonist that is in a third Phase II clinical trial in patients with primary biliary cholangitis; and Arhalofenate, which completed five Phase II clinical trials for the treatment of gout. The company's product candidate also includes MBX-2982, an oral, G-protein coupled receptor agonist to treat type II diabetes. Cymabay Therapeutics, Inc. has a development and license agreements with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders; and a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products. The company was formerly known as Metabolex, Inc. Cymabay Therapeutics, Inc. was incorporated in 1988 and is based in Newark, California.

Trade Information
Trade Type
LONG
ReliabilityScore™
96.15
Entry Date
Feb 7, 2017
Entry Price
2.05
Sell Date
Mar 21, 2017
Sell Price
3.97
Net Gain
93.65%
Hold Time
29 Trading Days